
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for …

Ipsen has announced the agreement to acquire oncology assets from Merrimack Pharmaceuticals, most notably the pancreatic cancer drug Onivyde, in …

Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

